Skip to content
Study details
Enrolling now

Droxidopa Trial

Giuseppe Cullaro, MD
NCT IDNCT06937307ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

75

Study length

about 2.6 years

Ages

18–70

Locations

1 site in NY

What this study is about

This trial is testing whether droxidopa, a medication, can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. The goal is to see if droxidopa helps raise blood pressure without intensive care or invasive treatments in 75 hospitalized patients with cirrhosis and kidney injury. Researchers will monitor changes in blood pressure and kidney function to determine if droxidopa is effective and safe for these patients.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Droxidopa capsules

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

droxidopa

Drug routes

oral (Oral Capsule)

Endpoints

Secondary: All-cause mortality, Change in serum creatinine

Body systems

Renal, Gastroenterology